Relay Therapeutics, Inc. RLAY Periodic Change In Costs To Obtain License Agreement Within Current Liabilities
Periodic Change In Costs To Obtain License Agreement Within Current Liabilities at other companies
Other financials
Where this comes from
Reported directly by Relay Therapeutics, Inc. in its filing.
Tagged under the XBRL concept rlay:PeriodicChangeInCostsToObtainLicenseAgreementWithinCurrentLiabilities.
The official record: Relay Therapeutics, Inc.’s 10-Q, filed May 5, 2026, on SEC EDGAR. View the filing →
Ask your AI about Relay Therapeutics, Inc.'s periodic change in costs to obtain license agreement within current liabilities.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Relay Therapeutics, Inc.'s periodic change in costs to obtain license agreement within current liabilities?
- Relay Therapeutics, Inc. (RLAY) reported periodic change in costs to obtain license agreement within current liabilities of $0 in Q1 2026.
- How has Relay Therapeutics, Inc.'s periodic change in costs to obtain license agreement within current liabilities changed year-over-year?
- Relay Therapeutics, Inc.'s periodic change in costs to obtain license agreement within current liabilities increased by 100.0% year-over-year, from -$2.51M to $0.
- What does periodic change in costs to obtain license agreement within current liabilities mean?
- This metric tracks the change in current liabilities related to obligations incurred to secure intellectual property or drug development licenses. It reflects the accrual of costs for licensing agreements that have not yet resulted in a cash disbursement. For biotech firms, this is a key indicator of near-term cash requirements for pipeline expansion and strategic partnerships.